All In Biotech

Drug Trial Radar · NCT00547287

Studying the Preference of Tadalafil to Sildenafil in Men With Problems Getting an Erection Across Nations

Switching From Sildenafil Citrate to Tadalafil in Treatment of Erectile Dysfunction: Multinational Assessment of Treatment Preference

Last checked: Nov 19, 2026Latest source record: Oct 22, 2007 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,760

Actual

Start

Nov 2002

Primary completion

Not stated

Study completion May 2004

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
Collaborators
ICOS Corporation
First posted
Oct 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Crossover
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to determine if men from around the world prefer sildenafil to tadalafil.

Conditions

  • Impotence

Interventions

  • tadalafilDrug

    20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.

  • sildenafilDrug

    Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient choice of treatment (either sildenafil or tadalafil) for use in the extension phaseTime frame: 14 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

    São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.